Homotaurine limits the spreading of T cell autoreactivity within the CNS and ameliorates disease in a model of multiple sclerosis
Open Access
- 8 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 11 (1), 1-8
- https://doi.org/10.1038/s41598-021-84751-3
Abstract
Most multiple sclerosis (MS) patients given currently available disease-modifying drugs (DMDs) experience progressive disability. Accordingly, there is a need for new treatments that can limit the generation of new waves T cell autoreactivity that drive disease progression. Notably, immune cells express GABAA-receptors (GABAA-Rs) whose activation has anti-inflammatory effects such that GABA administration can ameliorate disease in models of type 1 diabetes, rheumatoid arthritis, and COVID-19. Here, we show that oral GABA, which cannot cross the blood–brain barrier (BBB), does not affect the course of murine experimental autoimmune encephalomyelitis (EAE). In contrast, oral administration of the BBB-permeable GABAA-R-specific agonist homotaurine ameliorates monophasic EAE, as well as advanced-stage relapsing–remitting EAE (RR-EAE). Homotaurine treatment beginning after the first peak of paralysis reduced the spreading of Th17 and Th1 responses from the priming immunogen to a new myelin T cell epitope within the CNS. Antigen-presenting cells (APC) isolated from homotaurine-treated mice displayed an attenuated ability to promote autoantigen-specific T cell proliferation. The ability of homotaurine treatment to limit epitope spreading within the CNS, along with its safety record, makes it an excellent candidate to help treat MS and other inflammatory disorders of the CNS.Funding Information
- National Multiple Sclerosis Society (RG-1607-24947, RG-1607-24947, RG-1607-24947)
This publication has 43 references indexed in Scilit:
- Modulation of Neurological Deficits and Expression of Glutamate Receptors during Experimental Autoimmune Encephalomyelitis after Treatment with Selected Antagonists of Glutamate ReceptorsBioMed Research International, 2013
- Different Subtypes of GABA-A Receptors Are Expressed in Human, Mouse and Rat T LymphocytesPLOS ONE, 2012
- Oral Treatment with γ-Aminobutyric Acid Improves Glucose Tolerance and Insulin Sensitivity by Inhibiting Inflammation in High Fat Diet-Fed MicePLOS ONE, 2011
- Combining Antigen-Based Therapy with GABA Treatment Synergistically Prolongs Survival of Transplanted ß-Cells in Diabetic NOD MicePLOS ONE, 2011
- GABA exerts protective and regenerative effects on islet beta cells and reverses diabetesProceedings of the National Academy of Sciences of the United States of America, 2011
- Anaesthetic Impairment of Immune Function Is Mediated via GABAA ReceptorsPLOS ONE, 2011
- Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritisAutoimmunity, 2011
- Increased GABAA channel subunits expression in CD8+ but not in CD4+ T cells in BB rats developing diabetes compared to their congenic littermatesMolecular Immunology, 2011
- Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)Videosurgery and Other Miniinvasive Techniques, 2011
- Inhibitory role for GABA in autoimmune inflammationProceedings of the National Academy of Sciences of the United States of America, 2010